BMJ open · 2014
Bee venom acupuncture for rheumatoid arthritis: a systematic review of randomised clinical trials.
СтатьяСистематический обзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Lee Ju Ah, Son Mi Ju, Choi Jiae, Jun Ji Hee, Kim Jong-In, Lee Myeong Soo
Аннотация
OBJECTIVE: To assess the clinical evidence for bee venom acupuncture (BVA) for rheumatoid arthritis (RA).
DESIGN: Systematic review of randomised controlled trials (RCTs).
SETTING: We searched 14 databases up to March 2014 without a language restriction.
PARTICIPANTS: Patients with RA.
INTERVENTION: BVA involved injecting purified, diluted BV into acupoints. We included trials on BVA used alone or in combination with a conventional therapy versus the conventional therapy alone.
PRIMARY OUTCOMES: Morning stiffness, pain and joint swelling
SECONDARY OUTCOMES: Erythrocyte sedimentation rate (ESR), C reactive protein (CRP), rheumatoid factor, the number of joints affected by RA and adverse effects likely related to RA.
RESULTS: A total of 304 potentially relevant studies were identified; only one RCT met our inclusion criteria. Compared with placebo, BVA may more effectively improve joint pain, swollen joint counts, tender joint counts, ESR and CRP but was not shown to improve morning stiffness.
CONCLUSIONS: There is low-quality evidence, based on one trial, that BVA can significantly reduce pain, morning stiffness, tender joint counts, swollen joint counts and improve the quality of life of patients with RA compared with placebo (normal saline injection) control. However, the number of trials, their quality and the total sample size were too low to draw firm conclusions.
TRIAL REGISTRATION NUMBER: PROSPERO 2013: CRD42013005853.
DESIGN: Systematic review of randomised controlled trials (RCTs).
SETTING: We searched 14 databases up to March 2014 without a language restriction.
PARTICIPANTS: Patients with RA.
INTERVENTION: BVA involved injecting purified, diluted BV into acupoints. We included trials on BVA used alone or in combination with a conventional therapy versus the conventional therapy alone.
PRIMARY OUTCOMES: Morning stiffness, pain and joint swelling
SECONDARY OUTCOMES: Erythrocyte sedimentation rate (ESR), C reactive protein (CRP), rheumatoid factor, the number of joints affected by RA and adverse effects likely related to RA.
RESULTS: A total of 304 potentially relevant studies were identified; only one RCT met our inclusion criteria. Compared with placebo, BVA may more effectively improve joint pain, swollen joint counts, tender joint counts, ESR and CRP but was not shown to improve morning stiffness.
CONCLUSIONS: There is low-quality evidence, based on one trial, that BVA can significantly reduce pain, morning stiffness, tender joint counts, swollen joint counts and improve the quality of life of patients with RA compared with placebo (normal saline injection) control. However, the number of trials, their quality and the total sample size were too low to draw firm conclusions.
TRIAL REGISTRATION NUMBER: PROSPERO 2013: CRD42013005853.